Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study

NCT07398599 | Recruiting DMC

• 1 other identifier: IIT-2025-640
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to explore the efficacy and safety of double-dose third-generation EGFR-TKI combined with bevacizumab and intrathecal chemotherapy in treating advanced non-small cell lung cancer (NSCLC) patients with leptomeningeal metastasis that progressed after prior standard-dose third-generation EGFR-TKI treatment. It also aims to investigate the correlation between cerebrospinal fluid genetic characteristics and prognosis as well as subsequent efficacy prediction in patients with leptomeningeal metastasis after resistance to standard-dose third-generation EGFR-TKI. The main questions it intends to answer are: Does this combined treatment regimen improve leptomeningeal metastasis response rate (LM-ORR) evaluated by RANO-LM? What adverse events occur in patients during the treatment with this combined regimen? Researchers will conduct a single-arm phase II prospective study to assess the effectiveness and safety of the combined treatment, without a control group comparison. Participants will: Receive double-dose third-generation EGFR-TKI (osimertinib 160mg qd, furmonertinib 160mg qd, or almonertinib 220mg qd) + intrathecal pemetrexed (induction phase: 10mg twice a week for 4 weeks; maintenance phase: 10mg once a week for 4 weeks; consolidation phase: 30mg every 4 weeks until disease progression or intolerable toxicity) + bevacizumab 7.5mg/kg. Undergo screening assessments within 28 days before enrollment, including tumor imaging, laboratory tests, and cerebrospinal fluid examination. During the treatment period, conduct regular checkups and tests (such as blood routine, blood biochemistry, electrocardiogram, and imaging examinations) according to the protocol (once every 4 weeks in the first two treatment cycles, then once every 8 weeks). Complete quality of life assessment using the QLQ-C30 scale every 4 weeks and record changes in neurological symptoms and ECOG scores.

Conditions

Leptomeningeal Metastasis; Lung Neoplasms, Non-Small Cell Lung Cancer

Keywords

Leptomeningeal Metastasis; non-small cell lung cancer

Outcome Measures

Primary Outcomes (1)

• LM-ORR

  The primary endpoint is leptomeningeal metastasis overall response rate (LM-ORR) evaluated by RANO-LM criteria.

  Up to 30 days after the last study drug administration (for safety and response assessment), and through study completion, an average of 1 years (for survival follow-up)

Study Arms (1)

a combined regimen consisting of double-dose third-generation EGFR-TKI, bevacizumab, and intrathecal

EXPERIMENTAL

Combination Product: a combined regimen consisting of double-dose third-generation EGFR-TKI, bevacizumab, and intrathecal chemotherapy in patients

Interventions

a combined regimen consisting of double-dose third-generation EGFR-TKI, bevacizumab, and intrathecal chemotherapy in patients COMBINATION_PRODUCT

The combined treatment includes three components: double-dose third-generation EGFR-TKI (oral osimertinib 160mg once daily, furmonertinib 160mg once daily, or almonertinib 220mg once daily); intrathecal pemetrexed (administered via lumbar puncture, Ommaya reservoir, or intrathecal pump, with induction phase: 10mg twice weekly for 4 weeks, maintenance phase: 10mg once weekly for 4 weeks, consolidation phase: 30mg every 4 weeks until disease progression or intolerable toxicity); and bevacizumab 7.5mg/kg administered intravenously.

a combined regimen consisting of double-dose third-generation EGFR-TKI, bevacizumab, and intrathecal

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged ≥ 18 years at the time of signing the informed consent form, regardless of gender.
• Histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC), staged as IV according to the 8th edition of the IASLC TNM classification (2015).
• Presence of EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R mutation).
• Leptomeningeal metastasis (LM) progression after standard-dose first-, second-, or third-generation EGFR-TKI treatment.
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
• Adequate major organ function, defined as: hemoglobin (Hb) ≥ 90 g/L, absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L, platelet count (PLT) ≥ 100 × 10\^9/L, white blood cell count (WBC) ≥ 3.0 × 10\^9/L and ≤ 10.0 × 10\^9/L; total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN), alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 × ULN; creatinine clearance ≥ 50 ml/min (for patients with liver metastases, TBIL ≤ 3.0 × ULN, ALT and AST ≤ 5.0 × ULN); activated partial thromboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT) ≤ 1.5 × ULN.
• At least 21 days since the last radiotherapy (including whole-brain radiotherapy or local radiotherapy for brain metastases).
• Expected survival ≥ 3 months.
• Ability to swallow oral medications (or receive crushed medications via gastrostomy tube if unable to swallow).
• For women: Agreement to use effective contraception (e.g., surgical sterilization or protocol contraception) within 14 days prior to enrollment, during the study, and for 3 months after the last study drug administration.
• For men: Agreement to use effective contraception (e.g., surgical sterilization or protocol contraception) during the study and for 3 months after the last study drug administration.
• Voluntary participation, signed informed consent, and willingness to comply with study procedures and protocols.

You may not qualify if:

• Major surgery within 4 weeks prior to the start of study treatment, or need for major surgery during the study.
• Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
• Active bacterial/fungal/viral infections requiring intravenous antibiotic therapy.
• Drug-induced pneumonitis or interstitial lung disease, or evidence of clinically significant active pulmonary disease.
• Severe cardiovascular events within 6 months prior to enrollment, including cerebrovascular accident, deep vein thrombosis, or pulmonary embolism.
• Significant cardiovascular disease, such as New York Heart Association (NYHA) class II or higher congestive heart failure, unstable angina, symptomatic arrhythmias requiring treatment, or corrected QT interval (QTcF) \> 470 ms on consecutive electrocardiograms.
• History of other systemic malignant tumors within the past 5 years (except for cured basal cell carcinoma, carcinoma in situ of the cervix, and ovarian cancer).
• Use of drugs or supplements known to be strong inducers of CYP3A4.
• Known severe allergy to any study drug or its excipients.
• Pregnancy, lactation, or refusal of effective contraception by patients of childbearing potential.
• History of definite neurological or psychiatric disorders (including epilepsy and dementia).
• Other conditions deemed unsuitable for enrollment by the investigator.

Sponsors & Collaborators

• Second Affiliated Hospital of Nanchang University: lead

Study Sites (1)

The Second Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

RECRUITING

MeSH Terms

Conditions

Meningeal Carcinomatosis; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung

Interventions

Bevacizumab

Condition Hierarchy (Ancestors)

Meningeal Neoplasms; Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Nervous System Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Central Study Contacts

jing cai Jing Cai

CONTACT

15270905381; cjdl879@163.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 29, 2026
• First Posted: February 10, 2026
• Study Start: February 15, 2026
• Primary Completion (Estimated): December 30, 2027
• Study Completion (Estimated): December 30, 2027
• Last Updated: April 23, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)